No connection

Search Results

BDMD vs PLUR

BDMD
Baird Medical Investment Holdings Limited
BEARISH
Price
$1.03
Market Cap
$37.8M
Sector
Healthcare
AI Confidence
92%
PLUR
Pluri Inc.
BEARISH
Price
$3.51
Market Cap
$35.3M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
BDMD
--
PLUR
--
Forward P/E
BDMD
--
PLUR
-1.85
P/B Ratio
BDMD
0.77
PLUR
-2.4
P/S Ratio
BDMD
1.19
PLUR
26.35
EV/EBITDA
BDMD
51.6
PLUR
-2.58

Profitability

Gross Margin
BDMD
86.94%
PLUR
40.63%
Operating Margin
BDMD
-131.3%
PLUR
-3285.86%
Profit Margin
BDMD
-9.95%
PLUR
0.0%
ROE
BDMD
-8.03%
PLUR
--
ROA
BDMD
-0.2%
PLUR
-50.6%

Growth

Revenue Growth
BDMD
-39.4%
PLUR
7.0%
Earnings Growth
BDMD
--
PLUR
--

Financial Health

Debt/Equity
BDMD
0.63
PLUR
--
Current Ratio
BDMD
1.71
PLUR
0.43
Quick Ratio
BDMD
1.22
PLUR
0.39

Dividends

Dividend Yield
BDMD
--
PLUR
--
Payout Ratio
BDMD
0.0%
PLUR
0.0%

AI Verdict

BDMD BEARISH

The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of just 3/9, indicating poor financial health. Despite a seemingly reasonable Price/Book of 0.77 and a strong Gross Margin of 86.94%, the company is deeply unprofitable with negative operating and net margins, collapsing revenue, and no analyst coverage. The complete absence of Altman Z-Score and intrinsic value calculations, combined with a 5-year return of -89.3%, signals severe distress. Technical indicators and insider sentiment are also weak, reinforcing a high-risk outlook.

Strengths
High gross margin of 86.94% suggests strong pricing power or low production costs in core operations
Current ratio of 1.71 indicates short-term liquidity is manageable
Quick ratio of 1.22 shows the company can meet immediate obligations without relying on inventory
Risks
Piotroski F-Score of 3/9 indicates severe financial weakness and high risk of continued underperformance
Operating margin of -131.30% reflects deep operational inefficiencies or unsustainable cost structure
Revenue growth YoY of -39.40% shows rapid top-line contraction
PLUR BEARISH

PLUR exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -2.40, indicating negative shareholder equity. The company is facing a severe liquidity crisis with a current ratio of 0.43, suggesting it cannot meet its short-term obligations. While recent quarterly earnings have beaten estimates, the operating margin of -3285.86% and a bearish technical trend (0/100) underscore a high risk of insolvency or significant shareholder dilution. The valuation is disconnected from fundamentals, trading at a high Price/Sales multiple of 26.35 despite sluggish revenue growth.

Strengths
Recent quarterly earnings beats (3 of last 4 quarters)
Positive YoY EPS growth (+71%)
Gross margin remains positive at 40.63%
Risks
Negative equity (P/B -2.40) indicating insolvency risk
Severe liquidity shortage (Current Ratio 0.43)
Catastrophic operating losses (-3285.86% margin)

Compare Another Pair

BDMD vs PLUR: Head-to-Head Comparison

This page compares Baird Medical Investment Holdings Limited (BDMD) and Pluri Inc. (PLUR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile